NASDAQ:OMER - Omeros Stock Price, Price Target & More

$14.35 -0.07 (-0.49 %)
(As of 04/25/2018 06:42 AM ET)
Previous Close$14.42
Today's Range$13.84 - $14.85
52-Week Range$8.36 - $27.09
Volume740,500 shs
Average Volume1.30 million shs
Market Capitalization$696.28 million
P/E Ratio-18.16
Dividend YieldN/A
Beta3.62

About Omeros (NASDAQ:OMER)

Omeros logoOmeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:OMER
CUSIP68214310
Phone206-676-5000

Debt

Debt-to-Equity Ratio-29.93%
Current Ratio4.12%
Quick Ratio4.10%

Price-To-Earnings

Trailing P/E Ratio-18.16
Forward P/E Ratio-7.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$64.83 million
Price / Sales10.69
Cash FlowN/A
Price / CashN/A
Book Value($0.06) per share
Price / Book-239.17

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-53,480,000.00
Net Margins-82.50%
Return on EquityN/A
Return on Assets-40.03%

Miscellaneous

Employees173
Outstanding Shares48,290,000

How to Become a New Pot Stock Millionaire

Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros (NASDAQ:OMER) announced its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The biopharmaceutical company had revenue of $13.76 million for the quarter, compared to the consensus estimate of $21.94 million. The business's quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the company posted ($0.45) EPS. View Omeros' Earnings History.

When is Omeros' next earnings date?

Omeros is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Omeros.

What price target have analysts set for OMER?

7 brokers have issued 12 month price objectives for Omeros' stock. Their predictions range from $4.00 to $75.00. On average, they anticipate Omeros' stock price to reach $26.43 in the next year. View Analyst Ratings for Omeros.

What are Wall Street analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:
  • 1. WBB Securities analysts commented, "We are therefore continuing our Strong Buy recommendation with a continued One-Year Target Price of $75. Pass-through enables physicians to prescribe and bill Medicare for the cost of designated drugs in addition to the fixed fee for which treatment is administered. The text of the bill states, “In the case of a drug or biological whose period of pass-through status under this paragraph ended on December 31, 2017, and for which payment under this subsection was packaged into a payment for a covered OPD service (or group of services) furnished beginning January 1, 2018, such pass- through status shall be extended for a 2-year period beginning on October 1, 2018.” While not a guarantee, we also believe that this is a logical next step to permanent reimbursement by CMS, which takes place with the vast majority of all drugs. OMIDRIA is a combination drug that is administered during intra-ocular surgery." (3/26/2018)
  • 2. Maxim Group analysts commented, "Omeros reported 4Q17 financial results and Omidria sales were $13.8M vs. $21.7M in the prior quarter. BUT… in terms of units (no. of vials shipped), it is our understanding that the levels are flat with the prior period. In other words, this is partly a revenue recognition issue, triggered by the change in pass through status. The company recorded a net loss of $16.6M and ended the period with $84M in cash and another $17M in accounts receivable." (3/2/2018)
  • 3. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (3/1/2018)

Who are some of Omeros' key competitors?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 59)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 60)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 58)
  • Dr. Pamela Pierce Palmer M.D., Ph.D., Co-Founder (Age 55)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 61)

Has Omeros been receiving favorable news coverage?

News stories about OMER stock have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omeros earned a news sentiment score of 0.14 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $14.35.

How big of a company is Omeros?

Omeros has a market capitalization of $696.28 million and generates $64.83 million in revenue each year. The biopharmaceutical company earns $-53,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Omeros employs 173 workers across the globe.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.


MarketBeat Community Rating for Omeros (OMER)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  441 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  669
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Omeros (NASDAQ:OMER) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Omeros in the last 12 months. Their average twelve-month price target is $26.43, suggesting that the stock has a possible upside of 84.18%. The high price target for OMER is $75.00 and the low price target for OMER is $4.00. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.432.502.882.75
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $26.43$26.43$36.1667$37.40
Price Target Upside: 84.18% upside87.58% upside110.52% upside170.62% upside

Omeros (NASDAQ:OMER) Consensus Price Target History

Price Target History for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018HC WainwrightSet Price TargetBuy$34.00HighView Rating Details
3/26/2018WBB SecuritiesReiterated RatingBuy$75.00HighView Rating Details
3/23/2018WedbushDowngradeOutperform -> Neutral$47.00 -> $19.00HighView Rating Details
3/22/2018Maxim GroupBoost Price TargetBuy -> Buy$24.00 -> $25.00MediumView Rating Details
3/2/2018Needham & Company LLCDowngradeBuy -> Hold$9.01HighView Rating Details
3/1/2018Cantor FitzgeraldSet Price TargetHold$19.00HighView Rating Details
2/14/2018Bank of AmericaBoost Price Target$2.44 -> $4.00LowView Rating Details
11/2/2017CowenDowngradeOutperform -> Market PerformN/AView Rating Details
4/1/2017FBR & CoReiterated RatingBuyLowView Rating Details
12/5/2016UBSReiterated RatingReduceN/AView Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Omeros (NASDAQ:OMER) Earnings History and Estimates Chart

Earnings by Quarter for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER) Earnings Estimates

2018 EPS Consensus Estimate: ($0.25)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181$0.02$0.02$0.02

Omeros (NASDAQ OMER) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.35)N/AView Earnings Details
3/1/2018Q4 2017($0.22)($0.25)$21.94 million$13.76 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.34)($0.16)$17.82 million$21.66 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.23)$14.63 million$17.15 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.35)($0.34)$13.32 million$12.26 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.48)($0.20)$12.71 million$12.91 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.35)($0.37)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.38)($0.46)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.38)($0.24)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.42)($0.30)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.52)($0.33)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.40)($0.35)ViewN/AView Earnings Details
8/10/2010Q2 2010($0.34)($0.37)ViewN/AView Earnings Details
5/12/2010Q1 2010($0.33)($0.31)ViewN/AView Earnings Details
3/31/2010Q4 2009($0.27)($0.28)ViewN/AView Earnings Details
11/19/2009Q3 2009($0.33)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Omeros (NASDAQ:OMER) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Omeros (NASDAQ OMER) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 48.92%
Insider Trading History for Omeros (NASDAQ:OMER)
Insider Trading History for Omeros (NASDAQ:OMER)

Omeros (NASDAQ OMER) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2018Michael A JacobsenVPSell1,020$22.45$22,899.008,520View SEC Filing  
6/16/2017Michael A JacobsenVPSell12,000$24.95$299,400.0019,500View SEC Filing  
6/15/2017Michael A JacobsenVPSell24,000$21.20$508,800.002,650View SEC Filing  
4/12/2017Thomas J CableDirectorSell3,000$16.49$49,470.0040,067View SEC Filing  
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.841,987,025View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.001,987,025View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.401,987,025View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.601,801,381View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00179,597View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00179,497View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00179,497View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00179,497View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00179,497View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00179,497View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.0049,467View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00138,426View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16185,182View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Omeros (NASDAQ OMER) News Headlines

Source:
DateHeadline
Omeros (OMER) Expected to Post Quarterly Sales of $2.24 MillionOmeros (OMER) Expected to Post Quarterly Sales of $2.24 Million
www.americanbankingnews.com - April 20 at 2:34 AM
-$0.53 Earnings Per Share Expected for Omeros (OMER) This Quarter-$0.53 Earnings Per Share Expected for Omeros (OMER) This Quarter
www.americanbankingnews.com - April 18 at 3:08 PM
Omeros (OMER) Raised to "Hold" at Zacks Investment ResearchOmeros (OMER) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:43 PM
Omeros Corporation: Elucidating Formulary Expansion At The VAOmeros Corporation: Elucidating Formulary Expansion At The VA
seekingalpha.com - April 13 at 9:16 AM
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIAOmeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA
www.businesswire.com - April 13 at 9:16 AM
Omeros (OMER) Announces Upcoming Presentations of New Data on OMIDRIA at ASCRSOmeros (OMER) Announces Upcoming Presentations of New Data on OMIDRIA at ASCRS
www.streetinsider.com - April 13 at 9:16 AM
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery MeetingOmeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
finance.yahoo.com - April 13 at 9:16 AM
Added to Veterans Health Administration National FormularyAdded to Veterans Health Administration National Formulary
www.businesswire.com - April 12 at 9:51 AM
Omeros Corporation: What The Recent Credit Facility Amendment ForetellsOmeros Corporation: What The Recent Credit Facility Amendment Foretells
seekingalpha.com - April 12 at 9:51 AM
OMIDRIA® Added to Veterans Health Administration National FormularyOMIDRIA® Added to Veterans Health Administration National Formulary
finance.yahoo.com - April 12 at 9:51 AM
Omeros Co. (OMER) Receives Consensus Recommendation of "Hold" from AnalystsOmeros Co. (OMER) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 11 at 3:29 PM
Omeros (OMER) Reports Amendment of Credit FacilityOmeros (OMER) Reports Amendment of Credit Facility
www.streetinsider.com - April 11 at 9:38 AM
Omeros Announces Amendment of Credit FacilityOmeros Announces Amendment of Credit Facility
finance.yahoo.com - April 11 at 9:38 AM
Omeros (OMER) Rating Increased to Strong-Buy at Zacks Investment ResearchOmeros (OMER) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - April 6 at 12:43 PM
Omeros Corporation: Setting The Record StraightOmeros Corporation: Setting The Record Straight
seekingalpha.com - April 6 at 9:13 AM
Omeros (OMER) Cut to Hold at Zacks Investment ResearchOmeros (OMER) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 5:46 PM
Omeros (OMER) Upgraded to "Sell" at ValuEngineOmeros (OMER) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM
What Should Investors Know About Omeros Corporation’s (NASDAQ:OMER) Growth?What Should Investors Know About Omeros Corporation’s (NASDAQ:OMER) Growth?
finance.yahoo.com - April 4 at 4:40 PM
Omeros (OMER) Buy Rating Reaffirmed at HC WainwrightOmeros' (OMER) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 4 at 12:49 PM
Omeros: OMS-721 And HST-TMAs, What Does It All Mean?Omeros: OMS-721 And HST-TMAs, What Does It All Mean?
seekingalpha.com - April 3 at 4:47 PM
 Brokerages Expect Omeros Co. (OMER) Will Post Quarterly Sales of $2.24 Million Brokerages Expect Omeros Co. (OMER) Will Post Quarterly Sales of $2.24 Million
www.americanbankingnews.com - April 3 at 3:19 AM
 Brokerages Anticipate Omeros Co. (OMER) Will Post Earnings of -$0.53 Per Share Brokerages Anticipate Omeros Co. (OMER) Will Post Earnings of -$0.53 Per Share
www.americanbankingnews.com - April 1 at 3:17 PM
Omeros (OMER) Research Coverage Started at HC WainwrightOmeros (OMER) Research Coverage Started at HC Wainwright
www.americanbankingnews.com - April 1 at 11:52 AM
Omeros (OMER) Downgraded to Sell at Zacks Investment ResearchOmeros (OMER) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 31 at 9:24 PM
Analysts’ Ratings for Omeros and Peers in March 2018Analysts’ Ratings for Omeros and Peers in March 2018
finance.yahoo.com - March 29 at 4:51 PM
What’s behind Omeros’s Cash FlowWhat’s behind Omeros’s Cash Flow
finance.yahoo.com - March 29 at 4:51 PM
Why Omeros’s Revenue SurgedWhy Omeros’s Revenue Surged
finance.yahoo.com - March 29 at 4:51 PM
A Look at Omeros’s Promising Research PipelineA Look at Omeros’s Promising Research Pipeline
finance.yahoo.com - March 29 at 4:51 PM
Omeros (OMER) Buy Rating Reiterated at WBB SecuritiesOmeros' (OMER) Buy Rating Reiterated at WBB Securities
www.americanbankingnews.com - March 26 at 8:39 AM
Omeros shares surge 45% on spending bill that benefits its drugOmeros shares surge 45% on spending bill that benefits its drug
www.marketwatch.com - March 24 at 5:21 PM
Omeros (OMER) Upgraded at ValuEngineOmeros (OMER) Upgraded at ValuEngine
www.americanbankingnews.com - March 23 at 8:28 PM
Omeros (OMER) Rating Increased to Sell at BidaskClubOmeros (OMER) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 23 at 7:56 PM
Omeros (OMER) Downgraded by WedbushOmeros (OMER) Downgraded by Wedbush
www.americanbankingnews.com - March 23 at 6:50 PM
Omeros (OMER) Given Buy Rating at HC WainwrightOmeros (OMER) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - March 23 at 2:56 PM
New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros ScoresNew Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores
finance.yahoo.com - March 23 at 8:54 AM
ICYMI: GameStop, Omeros, Congress Impacts BiotechsICYMI: GameStop, Omeros, Congress Impacts Biotechs
feeds.benzinga.com - March 23 at 7:51 AM
Maxim Group Analysts Give Omeros (OMER) a $25.00 Price TargetMaxim Group Analysts Give Omeros (OMER) a $25.00 Price Target
www.americanbankingnews.com - March 22 at 3:18 PM
Mid-Day Market Update: Dow Falls Over 350 Points; Omeros Shares Spike HigherMid-Day Market Update: Dow Falls Over 350 Points; Omeros Shares Spike Higher
feeds.benzinga.com - March 22 at 2:31 PM
Omeros shares surge 63% on spending bill that benefits its drugOmeros shares surge 63% on spending bill that benefits its drug
finance.yahoo.com - March 22 at 9:06 AM
Omeros up 37% premarket on continuation Omidria pricingOmeros up 37% premarket on continuation Omidria pricing
seekingalpha.com - March 22 at 8:55 AM
$14.15 Million in Sales Expected for Omeros Co. (OMER) This Quarter$14.15 Million in Sales Expected for Omeros Co. (OMER) This Quarter
www.americanbankingnews.com - March 17 at 4:22 AM
Omeros Co. (OMER) Expected to Announce Earnings of -$0.34 Per ShareOmeros Co. (OMER) Expected to Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - March 15 at 1:51 PM
Financial Review: Zai Lab (ZLAB) versus Omeros (OMER)Financial Review: Zai Lab (ZLAB) versus Omeros (OMER)
www.americanbankingnews.com - March 15 at 11:30 AM
Omeros (OMER) Receives Buy Rating from HC WainwrightOmeros (OMER) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 5 at 11:49 AM
Is Omeros Corporation a Buy on the Dip?Is Omeros Corporation a Buy on the Dip?
finance.yahoo.com - March 5 at 10:02 AM
Omeros Co. (OMER) Shares Bought by Baird Financial Group Inc.Omeros Co. (OMER) Shares Bought by Baird Financial Group Inc.
www.americanbankingnews.com - March 5 at 4:58 AM
Maxim Group Analysts Give Omeros (OMER) a $24.00 Price TargetMaxim Group Analysts Give Omeros (OMER) a $24.00 Price Target
www.americanbankingnews.com - March 2 at 11:24 PM
Omeros (OMER) Downgraded to "Hold" at Needham & Company LLCOmeros (OMER) Downgraded to "Hold" at Needham & Company LLC
www.americanbankingnews.com - March 2 at 8:51 PM
Omeros (OMER) PT Set at $19.00 by Cantor FitzgeraldOmeros (OMER) PT Set at $19.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 2 at 12:28 PM
Today’s Research Reports on Trending Tickers: Omeros and Opko HealthToday’s Research Reports on Trending Tickers: Omeros and Opko Health
finance.yahoo.com - March 2 at 9:10 AM

SEC Filings

Omeros (NASDAQ:OMER) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Omeros (NASDAQ:OMER) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Omeros (NASDAQ OMER) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.